Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Core Insights - Kura Oncology, Inc. will report its fourth quarter and full year 2024 financial results on February 26, 2025, after U.S. market close [1] - A conference call and webcast will be held at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update [1] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment [3] - The company's pipeline includes small molecule drug candidates targeting cancer signaling pathways, with ziftomenib being a notable investigational therapy for relapsed/refractory NPM1-mutant acute myeloid leukemia [3] - Kura entered a global strategic collaboration with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies [3] - Enrollment in a Phase 2 registration-directed trial of ziftomenib for R/R NPM1-mutant AML has been completed [3] - Kura is also conducting clinical trials for ziftomenib in combination with current standards of care for newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML [3] - KO-2806, a next-generation farnesyl transferase inhibitor, is in a Phase 1 dose-escalation trial [3] - Tipifarnib, another farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for PIK3CA-dependent head and neck squamous cell carcinoma [3]